Analysis of doxorubicin distribution in MCF-7 cells treated with drug-loaded nanoparticles by combination of two fluorescence-based techniques, confocal spectral imaging and capillary electrophoresis.
The intracellular distribution of the antiancer drug doxorubicin (DOX) was followed qualitatively by fluorescence confocal spectral imaging (FCSI) and quantitatively by capillary electrophoresis (CE). FCSI permits the localization of the major fluorescent species in cell compartments, with spectral shifts indicating the polarity of the respective environment. However, distinction between drug and metabolites by FCSI is difficult due to their similar fluorochromes, and direct quantification of their fluorescence is complicated by quantum yield variation between different subcellular environments. On the other hand, capillary electrophoresis with fluorescence detection (CE-LIF) is a quantitative method capable of separating doxorubicin and its metabolites. In this paper, we propose a method for determining drug and metabolite concentration in enriched nuclear and cytosolic fractions of cancer cells by CE-LIF, and we compare these data with those of FCSI. Significant differences in the subcellular distribution of DOX are observed between the drug administered as a molecular solution or as a suspension of drug-loaded iron oxide nanoparticles coated with polyethylene glycol. Comparative analysis of the CE-LIF vs FCSI data may lead to a tentative calibration of this latter method in terms of DOX fluorescence quantum yields in the nucleus and more or less polar regions of the cytosol.
Universite Francois-Rabelais de Tours, EA6295 "Nanomedicaments et Nanosondes", 31 Avenue Monge, 37200, Tours, France.
Juliette
J
Gautier
Emilie
E
Munnier
Martin
M
Soucé
Igor
I
Chourpa
Laurence
L
Douziech Eyrolles
D002138:Calibration; D002467:Cell Nucleus / Q000737:chemistry / Q000187:drug effects; D003600:Cytosol / Q000737:chemistry / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D019075:Electrophoresis, Capillary / Q000379:methods*; D005290:Ferric Compounds / Q000737:chemistry; D005453:Fluorescence; D006801:Humans; D061986:MCF-7 Cells / Q000187:drug effects; D008280:Magnetics; D018613:Microscopy, Confocal / Q000379:methods*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry
D005290:Ferric Compounds; C000499:ferric oxide; D011092:Polyethylene Glycols; D004317:Doxorubicin